Live tape
Top 8, mentions 7d10,382TSLA2,416 mentions▲ +0.05SPCX1,886 mentions▲ +0.08GOOGL1,298 mentions▲ +0.04CRWV1,186 mentions▲ +0.04NVDA1,045 mentions▲ +0.07QQQ1,010 mentions▲ +0.05META776 mentions▲ +0.05NBIS765 mentions▲ +0.07

Equity · Healthcare

TRVI

NASDAQ

Trevi Therapeutics (TRVI)

$19 +9.48% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for TRVI to draw a line in its place.

Track this symbol on TradingView TradingView chart
Market cap $2.7B
52-week range $6.40 – $19.50
Avg volume 583.0K

as of Jul 17, 2026

Trevi Therapeutics (TRVI) insider trades

SEC Form 4 · last 90 days · newest reported trade 15 Sep 2026

In the 90 days to 21 Oct 2026, Trevi Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 2 Dec 2025, show no open-market purchase.

Open-market buys 0
Open-market sells 1
Net sold $596K
Non-trade filings 1
Date Insider Type Shares Value
15 Sep 2026 Heffernan Michael Thomas Director Sell 39,473 $596K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
15 Sep 2026 Heffernan Michael Thomas Director Option exercise 39,473 $126K

Trevi Therapeutics (TRVI) reported financials

SEC EDGAR XBRL SEC EDGAR

Trevi Therapeutics reported net income of −$42.8M for the fiscal year ended 31 Dec 2025.

Figure Reported Period
Net income −$42.8M 31 Dec 2025 fiscal year
Diluted EPS −$0.32 31 Dec 2025 fiscal year
Total assets $330.5M 30 Jun 2026 at period end
Total equity $321.5M 30 Jun 2026 at period end

Trevi Therapeutics (TRVI) earnings

SEC EDGAR

Trevi Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.11; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.11 —
31 Mar 2026 Q1 2026 −$0.09 —
31 Dec 2025 FY 2025 −$0.32 —
30 Sep 2025 Q3 2025 −$0.08 —
30 Jun 2025 Q2 2025 −$0.09 —
31 Mar 2025 Q1 2025 −$0.09 —
31 Dec 2024 FY 2024 −$0.47 —
30 Sep 2024 Q3 2024 −$0.13 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Trevi Therapeutics (TRVI) institutional holders (13F)

SEC Form 13F SEC EDGAR

5 of the 45 institutional funds we track reported a Trevi Therapeutics position for the quarter ended 30 Jun 2026 — a combined $101.1M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Marshall Wace Trimmed −32.6% shares 2,674,137 $49.9M
Viking Global Investors Trimmed −51.7% shares 1,544,644 $28.8M
Balyasny Asset Management Added +78.3% shares 845,087 $15.8M
D. E. Shaw & Co. Added +55.5% shares 281,996 $5.3M
Tudor Investment Corp Held (±25%) +14.7% shares 73,978 $1.4M
AQR Capital Management Exited
Citadel Advisors Exited
Millennium Management Exited
Two Sigma Investments Exited

Trevi Therapeutics (TRVI) fails-to-deliver

SEC CNS data SEC

On 22 Sep 2026, 6,351 shares of Trevi Therapeutics failed to deliver (about $95K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
22 Sep 2026 6,351 $95K 0.004%
21 Sep 2026 6,350 $95K 0.004%

Trevi Therapeutics (TRVI): frequently asked questions

From live data

Have Trevi Therapeutics insiders bought or sold shares recently?

In the 90 days to 21 Oct 2026, Trevi Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 2 Dec 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade.

How many institutions hold Trevi Therapeutics?

5 of the 45 institutional funds we track reported a Trevi Therapeutics position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Trevi Therapeutics had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Trevi Therapeutics is dated 22 Sep 2026, when 6,351 shares failed to deliver.

When did Trevi Therapeutics last report earnings?

Trevi Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.11; no next date is announced in SEC filings yet.

What exchange is Trevi Therapeutics listed on?

Trevi Therapeutics trades on NASDAQ under the ticker TRVI.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings